advertisement
Shams NK 16
Showing records 1 to 16 |
Display all abstracts from Shams NK94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)Olander KW
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive MonkeysFuwa M
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)Sato MA
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive MonkeysShimazaki A
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)Abrams MA
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive MonkeysOdani-Kawabata N; Kirihara T
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)Jerkins GW
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive MonkeysTaniguchi T
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)Lu F
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive MonkeysIwamura R; Iwamura R
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)Dinh P
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive MonkeysYoneda K
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)Odani-Kawabata N
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive MonkeysKato M
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)Chabi A; Shams NK
Journal of Glaucoma 2021; 30: 473-480
95174 Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive MonkeysMorishima K; Shams NK
Journal of Ocular Pharmacology and Therapeutics 2021; 37: 223-229
Issue 22-2
Change Issue
advertisement